The all-in-one diagnostic platform combines hematology, biochemistry, and immunoassay testing in a single run.
Ozelle launched its next-generation AI + Complete Blood Morphology (CBM) solution at MEDICA 2025 in Düsseldorf, Germany, introducing an integrated diagnostic platform that performs hematology, biochemistry, and immunoassay testing simultaneously.
The new solution aims to address a growing demand for rapid and standardized testing by consolidating multiple testing workflows into a single system, according to a release from the company. The platform is designed to make advanced diagnostics more accessible across different levels of care, from large laboratories to smaller clinical settings.
According to the company, the solution features three key technological advances:
- All-in-One, Flexible Testing: Performs multiple assays in one run, combining CBC with HbA1c, GLU/TG/TC/UA, TSH, FT3/FT4, CRP, or SAA—any combination as needed to support diverse clinical needs. From infection typing to diabetes and thyroid function panels, it supports tiered testing and versatile clinical applications ranging from outpatient clinics to POCT settings.
- AI + CBM, Smarter Diagnosis:Â Powered by AI+CBM, it detects abnormal cells with lab-grade precision and provides intelligent diagnostic insights within six minutes.
- Simple to Use, Maintenance-Free:Â A one-click, fully automated workflow with single-use reagent kits. No sample pre-treatment, no cold-chain storage, and a maintenance-free design ensure effortless operation and reliability in any clinical environment.
“Our mission is to make expert-level morphology and intelligent diagnostics accessible to every laboratory, every clinic, every day,” according to a release from the company.
The company positions the solution as part of a broader ecosystem vision focused on connected intelligence, where individual tests contribute to improved patient outcomes through integrated data analysis.
ID 24529555 © Astroid | Dreamstime.com
